Login
$TNYA
$0.34 +$0.01 (1.92%) After hours

$TNYA 8-K SEC Filings

Filed On Filing
04 Nov 2026 8-K: Results of Operations and Financial Condition

Received Regenerative Medicine Advanced Therapy (RMAT) Designation from U.S. FDA for TN-401 Gene Therapy for PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

05 Aug 2026 8-K: Results of Operations and Financial Condition

Positive Interim Data Shared in 2Q 2026 from the MyPEAK™-1 and RIDGE™-1 Clinical Trials Each Demonstrated Meaningful Improvements in Key Disease Characteristics

02 Jul 2026 8-K: Termination of a Material Definitive Agreement

On June 29, 2026, Tenaya Therapeutics, Inc. (the “Company”) entered into a Lease Termination Agreement with Terreno Park Union City LLC to terminate the Company’s lease for approximately 94,046 rentable square feet at 33498 Central Avenu...

29 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

On behalf of Tenaya Therapeutics, Inc. (“Tenaya” or the “Company”), I am pleased to invite you to join the Company as Chief Financial Officer, reporting to the Company’s Chief Executive Officer. Your primary work location will be Thousan...

29 May 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

to attract and retain the best available personnel for positions of substantial responsibility,

06 May 2026 8-K: Results of Operations and Financial Condition

One-Year Cohort 1 Data and Initial Cohort 2 Data from RIDGE™-1 Phase 1b/2 Trial of TN-401 for PKP2-Associated ARVC to be Presented at ASGCT 2026

11 Mar 2026 8-K: Results of Operations and Financial Condition

Reported Promising Data for TN-201 and TN-401 Gene Therapies in Fourth Quarter of 2025; Additional Data Readouts and Pursuit of Regulatory Alignment for Each Program Planned in 2026

05 Mar 2026 8-K: Entry into a Material Definitive Agreement

On March 4, 2026, Tenaya Therapeutics, Inc. (the “Company”) entered into a collaboration agreement (the “Collaboration Agreement”) with Alnylam Pharmaceuticals, Inc. (“Alnylam”), pursuant to which the parties agreed to a research collabo...

30 Jan 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule; Departure/Election of Directors or Officers; Compensation

Purposes of the Plan. The purpose of this Plan is to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals entering into employment with the Company...

02 Jan 2026 8-K: Departure/Election of Directors or Officers; Compensation

On December 31, 2025, in connection with his retirement, David Goeddel submitted his resignation from the board of directors (the “Board”) of Tenaya Therapeutics, Inc. (the “Company”) and as a member of all committees of the Board, effec...

12 Dec 2025 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

As Representatives of the several Underwriters named in Schedule I hereto

11 Dec 2025 8-K: Regulation FD Disclosure; Other Events

Robust Transduction and Demonstrated Increases in PKP2 Protein Levels in First Two Patients at Week 8

10 Nov 2025 8-K: Results of Operations and Financial Condition

Presentation of MyPEAK-1 Data and the American Heart Association Scientific Sessions Showed Consistent, Deeper, and Durable Improvement in Measures of Hypertrophy for Cohort 1 Patients

07 Nov 2025 8-K: Other Events

The U.S. Food and Drug Administration (“FDA”) has placed a clinical hold on MyPEAKTM-1, Tenaya Therapeutics, Inc.’s (“Tenaya”) Phase 1b/2a clinical trial evaluating TN-201 in MYBPC3-associated hypertrophic cardiomyopathy, requesting an a...

06 Aug 2025 8-K: Results of Operations and Financial Condition

Enrollment Complete in Cohorts 1 and 2 of MyPEAKTM-1 Phase 1b/2 Trial of TN-201 for MYBPC3-associated HCM; Positive DSMB Safety Review Enables Enrollment of Expansion Cohorts

30 May 2025 8-K: Submission of Matters to a Vote of Security Holders

Tenaya Therapeutics, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”) on May 28, 2025. The matters voted upon at the Annual Meeting and the voting results for each proposal are set forth below. Voting r...

07 May 2025 8-K: Results of Operations and Financial Condition

Interim Data from Low Dose Cohort in MyPEAKTM-1 Clinical Trial of TN-201 Showed Encouraging Safety Profile, Transduction and Expression, Plus Improvements in Hypertrophy and NYHA Classification

18 Apr 2025 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

On April 15, 2025, Tenaya Therapeutics, Inc. (the “Company”) received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of shares of t...

28 Mar 2025 8-K: Costs Associated with Exit or Disposal Activities

On March 27, 2025, Tenaya Therapeutics, Inc. (“Tenaya”) approved the implementation of a restructuring plan (the “Restructuring Plan”) to further focus company resources on generating data from MyPEAKTM-1, evaluating TN-201 as a gene the...

10 Mar 2025 8-K: Results of Operations and Financial Condition

Dosing Initiated in Cohort 2 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support